Lion TCR Pte Ltd, a Singapore-based clinical stage biotech pioneering T cell therapy against viral- related cancer, raised US$20m in Series A financing round.
The round was led by undisclosed existing investors and other new investors such as Yashang Capital and Westlake Ventures Capital.
The company intends to use the funds to advance its on-going clinical trials of its lead candidate LioCyx™ (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B.
Led by Dr. Victor Li, founder and CEO, and scientific founder, Prof. Antonio Bertoletti, Lion TCR is a clinical stage biotech company focusing on development of engineered T-cell immunotherapy against viral-related cancer and chronic hepatitis B with manufacturing and clinical trial operations in China and Singapore.
Lion TCR’s engineer T cell technologies are exclusively licensed initially from Agency for Science, Technology and Research (A*STAR), Singapore (TCR-T cell therapy developed by Prof. Antonio Bertoletti’s lab) and lately from Technical University of Munich (CAR-T cell therapy developed by Prof. Urlike Protzer’s lab).